Abstract
The A Disintegrin And Metalloprotease (ADAM) proteins belong to the metzincin-superfamily of Zndependent metalloproteinases that shed the extracellular domains of membrane-bound growth factors, cytokines and their receptors. The latter play a central role in cell signaling and contribute a potential target in cancer therapy. Of particular interest are the ErBB/HER family of growth factor receptors associated with elevated intrinsic tyrosine kinase activity. Overexpression of ADAMs and cell signaling components have also been implicated in the development and progression of a variety of tumor types. Emerging evidence has suggested that the ADAM proteins are involved in tumour cell proliferation, in angiogenesis as well as metastasis. Therefore, strategies targeting ADAMs may constitute an important target for the design of cancer drugs. The review will focus on current understanding of the role of ADAM in the physiological and pathological functions associated with cancer. It is the intention of the review to provide insights which may assist in the development of ADAM-based approaches for the treatment of human cancers.
Keywords: ADAM protein, disintegrins, RGD motif, integrin, disintegrin-like domain, VEGFR, ERBB receptor
Current Cancer Drug Targets
Title: ADAM Proteins- Therapeutic Potential in Cancer
Volume: 8 Issue: 8
Author(s): Xinjie Lu, Dong Lu, Mike Scully and Vijay Kakkar
Affiliation:
Keywords: ADAM protein, disintegrins, RGD motif, integrin, disintegrin-like domain, VEGFR, ERBB receptor
Abstract: The A Disintegrin And Metalloprotease (ADAM) proteins belong to the metzincin-superfamily of Zndependent metalloproteinases that shed the extracellular domains of membrane-bound growth factors, cytokines and their receptors. The latter play a central role in cell signaling and contribute a potential target in cancer therapy. Of particular interest are the ErBB/HER family of growth factor receptors associated with elevated intrinsic tyrosine kinase activity. Overexpression of ADAMs and cell signaling components have also been implicated in the development and progression of a variety of tumor types. Emerging evidence has suggested that the ADAM proteins are involved in tumour cell proliferation, in angiogenesis as well as metastasis. Therefore, strategies targeting ADAMs may constitute an important target for the design of cancer drugs. The review will focus on current understanding of the role of ADAM in the physiological and pathological functions associated with cancer. It is the intention of the review to provide insights which may assist in the development of ADAM-based approaches for the treatment of human cancers.
Export Options
About this article
Cite this article as:
Lu Xinjie, Lu Dong, Scully Mike and Kakkar Vijay, ADAM Proteins- Therapeutic Potential in Cancer, Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733478
DOI https://dx.doi.org/10.2174/156800908786733478 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oncolytic Viruses: Programmable Tumour Hunters
Current Gene Therapy TGFb and its Smad Connection to Cancer
Current Genomics Fiber-Optic Technologies in Laser-Based Therapeutics: Threads for a Cure
Current Pharmaceutical Biotechnology Endothelial Colony Forming Capacity is Related to C-Reactive Protein Levels in Healthy Subjects
Current Neurovascular Research Targeting Apoptotic Signaling Pathways in Human Lung Cancer
Current Cancer Drug Targets Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Activity Based Chemical Proteomics: Profiling Proteases as Drug Targets
Current Drug Discovery Technologies Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Host Pharmacogenetics in the Treatment of HIV and Cancer
Current Drug Safety Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Identification of WHO II/III Gliomas by 16 Prognostic-related Gene Signatures using Machine Learning Methods
Current Medicinal Chemistry A Role for Calcineurin in Alzheimers Disease
Current Neuropharmacology Recent Advances in Liposomal Drug Delivery: A Review
Pharmaceutical Nanotechnology Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems
Recent Patents on Anti-Cancer Drug Discovery CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry Targeting PPARalpha in Alzheimer's Disease
Current Alzheimer Research Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Vasotrophic Regulation of Age-Dependent Hypoxic Cerebrovascular Remodeling
Current Vascular Pharmacology